Sharemaestro Newsreel

YD Bio Launches Cross-Border Cancer Testing Pilot With Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and Numia Health have partnered to launch a pilot program offering cross-border molecular diagnostic testing for cancer patients in Canada. This initiative aims to improve access to advanced genomic testing, enabling Canadian oncologists to make more informed treatment decisions. The program will …

How Investors Are Reacting To Guardant Health (GH) Spotlighting Shield Test And Teeing Up Earnings

Guardant Health is gaining investor attention following a colorectal cancer screening awareness campaign featuring Patrick Dempsey for its FDA-approved Shield blood test and ahead of its upcoming quarterly earnings report. The Shield test is the only FDA-approved blood test included in major colorectal cancer …

Illumina Looks Likely To Benefit From AI Initiatives in Life Sciences

Illumina is expected to gain from the growing integration of AI in life sciences, as highlighted by strong instrument sales and increasing AI opportunities boosting its 2026 outlook. The company's strategy involves leading genomic sequencing through innovation and acquisitions, addressing broad applications from population …

Mettler-Toledo International (NYSE:MTD) Issues Q3 2026 Earnings Guidance

Mettler-Toledo International (NYSE:MTD) has issued its Q3 2026 earnings guidance, projecting EPS between $12.00-$12.15, largely aligning with the consensus estimate. The company also maintained its revenue guidance at approximately $1.1 billion and updated its full-year 2026 EPS guidance to $47.15–$47.50. Despite a mixed analyst …

Labcorp Holdings Inc. Stock 12‑Month Price Target Raised to $317.31, Implies 3% Upside

Labcorp Holdings Inc. (LH) has seen its average 12-month price target raised to $317.31 from $313.56 by 16 analysts, implying a 3% potential upside from its July 29 closing price. The consensus rating for the stock remains a "Buy" among 22 covering analysts, with …

Veracyte Releases Q2 2026 Financial Results

Veracyte (NASDAQ: VCYT) reported strong Q2 2026 financial results, with non-GAAP EPS of $0.54, surpassing estimates, and revenue of $150.3M, exceeding expectations by 4.0%. The company's Decipher Prostate test was a key growth driver, and full-year revenue guidance is set at $590.0M to $596.0M. …

Earnings call transcript: Myriad Genetics sinks after Q2 2026 revenue miss

Myriad Genetics reported Q2 2026 revenue of $190.7 million, missing Wall Street forecasts, and posted an adjusted loss of $0.25 per share, wider than expected. Shares fell sharply by over 31% in after-hours trading. The company cut its full-year revenue guidance and suspended adjusted …

Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) has updated its FY 2026 earnings guidance, projecting an EPS of -$2.35 to -$2.22 and revenue of $330 million to $340 million, which falls below consensus estimates. The company also missed Q2 earnings expectations, reporting an adjusted EPS of -$0.58 and …

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

Illumina (NASDAQ:ILMN) reported strong Q2 CY2026 results, with revenue of $1.16 billion exceeding analyst expectations and sales up 9.4% year-on-year. The company also raised its full-year revenue guidance to $4.62 billion and adjusted EPS guidance to $5.35 at the midpoint, both slightly above analyst …

CDNA Looks 77.9% Overvalued on GF Value™ Amid Revenue Upgrade

Earnings call transcript: Castle Biosciences tops Q2 2026 estimates, shares jump

Castle Biosciences (CSTL) exceeded second-quarter 2026 profit and revenue estimates, leading to a significant jump in its share price and an increase in full-year sales guidance. The company reported an adjusted loss of 7 cents per share on revenue of $103.5 million, outperforming analyst …

Mettler-Toledo (NYSE:MTD) Reports Q2 CY2026 In Line With Expectations

IDEXX Laboratories Inc. stock outperforms competitors despite losses on the day

IDEXX Laboratories Inc. (IDXX) shares declined by 1.93% on Thursday, closing at $558.80, despite a generally positive trading session for the broader market. This drop ended a four-day winning streak for the company's stock.

Is Castle Biosciences (CSTL) Undervalued After Q2 Earnings Miss? GF Score: 81/100, Revenue at $103.5 Million

Earnings Flash (MTD) Mettler-Toledo International Inc. Reports Q2 Revenue $1.03B, vs. FactSet Est of $1.03B

Mettler-Toledo International Inc. (MTD) reported its Q2 revenue at $1.03 billion, matching FactSet's estimate. The company's Q2 adjusted earnings and revenue both saw an increase, and Mettler-Toledo also provided Q3 adjusted EPS guidance in the range of $12.00 to $12.15. This financial update aligns …

Adaptive Biotechnologies (NASDAQ: ADPT) insider reports Rule 10b5-1 stock sales

Adaptive Biotechnologies insider Susan Bobulsky has filed planned stock sales under a Rule 10b5-1 trading plan. The Form 144 filing details multiple open-market sales of common shares on NASDAQ in June and July 2026, totaling 26,487 shares for proceeds of $521,214.00. The sales are …

Mettler Toledo reports Q2 revenue $1.027B, adjusted EPS $11.46, strong margin improvement

Mettler Toledo (MTD) announced strong Q2 2026 results with net sales of $1.027 billion and adjusted diluted EPS of $11.46, marking a 14% increase year-over-year. The company attributed its margin and earnings gains to organic sales growth, improved market conditions, and benefits from its …

Mettler-Toledo: Q2 Earnings Snapshot

Mettler-Toledo International Inc. reported strong second-quarter results, with net income of $232.9 million, or $11.55 per share. Adjusted earnings of $11.46 per share surpassed Wall Street expectations, as did their revenue of $1.03 billion. The company also provided an optimistic outlook for its third …

Agilent Technologies Inc. stock underperforms Thursday when compared to competitors

Agilent Technologies Inc. (A) stock fell by 1.13% on Thursday, closing at $138.71. This underperformance occurred despite a favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both rising. This marks the second consecutive day of …

Veracyte Q2 revenue rises 15% to $150.3 million

Mettler-Toledo International Inc. Reports Second Quarter 2026 Results

Mettler-Toledo International Inc. (NYSE: MTD) announced strong second-quarter 2026 results, with reported sales increasing 4% and diluted EPS at $11.55. Adjusted EPS rose 14% to $11.46, driven by robust organic sales growth, particularly in China and emerging markets. The company also provided an optimistic …

Earnings Flash (CDNA) CareDx, Inc. Reports Q2 Revenue $131.9M, vs. FactSet Est of $113.8M

CareDx, Inc. (CDNA) reported Q2 revenue of $131.9 million, surpassing the FactSet estimate of $113.8 million. The company also announced adjusted EPS of $0.37 per share, significantly higher than the FactSet estimate of $0.23 per share. These financial results indicate a strong performance for …

Illumina’s 43% quarter meets a 58% Fair Value premium and thin volume near the high

Illumina closed at $194.10, only 2.5% below its 52-week high, but the latest 4.0% advance came on 0.8x 13-week average volume.

CareDx, Inc. (CDNA) Q2 2026 Earnings

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the …

Earnings Flash (ILMN) Illumina, Inc. Posts Q2 Adjusted EPS $1.31 per Share, vs. FactSet Est of $1.23

Illumina, Inc. (ILMN) announced its Q2 adjusted EPS of $1.31 per share, surpassing FactSet’s estimate of $1.23. The company also reported Q2 revenue of $1.16 billion, exceeding FactSet's estimate of $1.13 billion, and provided earnings guidance for fiscal year 2026. The news highlighted the …

Earnings Flash (ILMN) Illumina, Inc. Reports Q2 Revenue $1.16B, vs. FactSet Est of $1.13B

Illumina, Inc. (ILMN) reported its second-quarter revenue at $1.16 billion, surpassing FactSet's estimate of $1.13 billion. The company specializes in DNA sequencing and array-based technologies for research, clinical, and applied markets, with products used in life sciences, oncology, reproductive health, and agriculture. Illumina also …

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

Mdxhealth SA (NASDAQ: MDXH) announced it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. The company will host a conference call with live Q&A on the same day at 4:30 PM ET / 10:30 PM CET …

Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.54 per Share, Vs. FactSet Est of $0.43

Veracyte, Inc. (VCYT) reported its Q2 adjusted EPS of $0.54 per share, significantly surpassing the FactSet estimate of $0.43 per share. This financial update highlights the company's strong performance during the second quarter.

Castle Biosciences Reports Second Quarter 2026 Results

Guardant Health: Q2 Earnings Snapshot

Guardant Health Inc. (GH) reported a Q2 loss of $120.1 million, or 90 cents per share, which adjusted to 42 cents per share. This loss exceeded Wall Street's expectation of 40 cents per share. However, the oncology testing services provider surpassed revenue forecasts, posting …

PRLD|Prelude Therapeutics Inc|Price:4.520|Chg%:+0.130

This article provides a comprehensive stock analysis of Prelude Therapeutics Inc (PRLD) by TradingKey, highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, with a …

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Illumina, Inc. announced strong financial results for the second quarter of fiscal year 2026, with revenue reaching $1.16 billion, a 9.5% increase from Q2 2025. The company raised its fiscal year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40, …

Illumina, Inc. (Nasdaq: ILMN) lifts 2026 outlook after Q2 revenue hits $1.16B

Illumina, Inc. (Nasdaq: ILMN) reported strong Q2 2026 financial results with revenue reaching $1.16 billion, a 9.5% increase from the previous year. This performance led the company to raise its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. …

Adaptive Biotechnologies Number of Employees 2026 | Employee Count & Headcount Data

Adaptive Biotechnologies (NASDAQ: ADPT) had approximately 632 employees worldwide as of March 2026, a decline of 18.7% from 777 employees in 2023. Despite the overall headcount decline, the company is actively hiring, with 53 active job postings in 2026, a 40.9% increase from 2025. …

Natera to Report its Second Quarter Results on August 6, 2026

Natera, Inc. announced it will release its second-quarter 2026 financial results after market close on August 6, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investor and …